IMGN News and Press, ImmunoGen Inc. From 12/03/23

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-02 02:24:45 ET Summary AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. ImmunoGen's recent success with its drug ELAHERE, which received accelerated approval for the treatment of ovarian cance...

2023-12-01 14:45:02 ET Summary AbbVie Inc. is acquiring ImmunoGen, Inc. at a 94.6% premium, with shares now trading at a 6.6% upside to the deal's successful closing. The likelihood of an overbid is low due to a high termination fee and the current state of the biotech industry. ...

NEW YORK, NY / ACCESSWIRE / December 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Rover Group, Inc. (NASDAQ:RO...

NEW YORK, NY / ACCESSWIRE / December 1, 2023 / Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and h...

2023-12-01 08:52:41 ET More on AbbVie, ImmunoGen, etc. AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained AbbVie: Get Ready For More Painful Downside AbbVie-ImmunoGen ...

2023-11-30 19:19:34 ET The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV) , enjoyed a nearly 3% lift after the news was announced, contrasting quite favorabl...

2023-11-30 16:03:03 ET Summary AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian cancer treatment, and enhancing its oncology portfolio. ImmunoGen's advanced ADC pipeline, including potential blockbusters, complements AbbVie's existing prog...

2023-11-30 15:10:23 ET Summary AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline and potentially transforming its cancer care business. ImmunoGen's antibody drug conjugate, Elahere, is approved to treat ovarian cance...

2023-11-30 14:54:50 ET Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share of Im...